Gefitinib: re-emerging from the shadows

Author： Martin Petra   Owen Scott P   Leighl Natasha B  

Publisher： Future Medicine

ISSN： 1758-1966

Source： Lung Cancer Management, Vol.2, Iss.5, 2013-10, pp. : 423-437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature

By        

Oncology Letters, Vol. 9, Iss. 5, 2015-01 ,pp. : 2419-2421

Spandidos Publications

Access to resources Recommend Favorite

Resistance to gefitinib

By Uramoto Hidetaka   Sugio Kenji   Oyama Tsunehiro   Sugaya Masakazu   Hanagiri Takeshi   Yasumoto Kosei  

International Journal of Clinical Oncology, Vol. 11, Iss. 6, 2006-12 ,pp. : 487-491

Springer Publishing Company

Access to resources Recommend Favorite

Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib

By Tetsumoto Satoshi  

International Journal of Clinical Oncology, Vol. 17, Iss. 2, 2012-04 ,pp. : 155-159

Springer Publishing Company

Access to resources Recommend Favorite

Getting to grips with gefitinib

By Renee Bailey L.   Janas M.  

Lancet Oncology, Vol. 4, Iss. 12, 2003-12 ,pp. : 719-720

Elsevier

Access to resources Recommend Favorite

Acute gefitinib-induced pneumonitis

By Ohyanagi Fumiyoshi   Ando Yuichi   Nagashima Fumio   Narabayashi Masaru   Sasaki Yasutsuna  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 406-409

Springer Publishing Company

Access to resources Recommend Favorite